11 results about "CXCL13" patented technology

Provided herein are methods of making tumor reactive peripheral blood lymphocytes (trPBLs) using PBMCs obtained from a patient. The method comprises enriching trPBLs from PBMCs using markers that are expressed or secreted by the trPBLs, such as 4- IBB, CD103, CXCL13, IFN-y, CXCR6, CD200, HLA-DR, CD69, PD-1, CD39, CD38, CD49a, etc. Further provided are use of the trPBLs or pharmaceutical compositions thereof for the treatment of cancers.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

The invention relates to an application of a CXCL13 + CD8 + T cell subset in preparation of a product for predicting prognosis of a melanoma patient, and the CXCL13 + CD8 + T cell subset is used as an analysis target to prepare a reagent for analyzing immune cell functions. Wherein the CXCL13 < + > CD8 < + > T cell subset refers to a CD8 < + > T cell subset capable of releasing a CXCL13 signal. Compared with the prior art, the research shows that by analyzing the expression level of effector molecules and immune checkpoint molecules in a tumor microenvironment and the density of a three-level lymph structure, the prognosis of a tumor patient can be more accurately predicted, and the reactivity of tumors to immunotherapy can be predicted; at present, a report for reflecting immune characteristics of melanoma by using the CXCL13 + CD8 + T cell subset as a biomarker is not found. The infiltration level of CXCL13 + CD8 + T cells in tumor tissues is quantitatively evaluated through flow cytometry, and more accurate and sensitive indexes are provided for prognosis evaluation of melanoma and liver cancer patients.

The invention provides an anti-human CXCL13 rabbit monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of immune globulin, the anti-human CXCL13 rabbit monoclonal antibody can be specifically combined with CXCL13 protein, the specificity and sensitivity of immunodetection are remarkably improved, the anti-human CXCL13 rabbit monoclonal antibody is suitable for preparing an immunohistochemical detection kit, and the anti-human CXCL13 rabbit monoclonal antibody can be used for preparing immunohistochemical detection products. CXCL13 protein expression can be accurately detected, and a reliable tool is provided for diagnosis of diseases such as vascular immune maternal T cell lymphoma and peripheral T cell lymphoma.

The application discloses application of DUF3109 protein in preparation of an antitumor drug, wherein the DUF3109 protein is Bacteroides ovatus DUF3109 protein. The DUF3109 protein can inhibit the progression of liver cancer by regulating CD4+ T cell secretion of CXCL13 and promoting the formation of intratumoral tertiary lymphoid structures. In specific embodiments, the DUF3109 protein exhibits significant inhibitory effect on liver orthotopic tumors and significant promotion of CD4+ T lymphocyte and Jurkat cell secretion of CXCL13. The technical scheme of the application not only expands the use of the DUF3109 protein, but also provides a potential innovative solution for tumor treatment and a new research direction for development of an antitumor drug.

Provided herein are methods and immune biomarkers for identifying multiple sclerosis (MS) progression and treatment options. Materials and methods for prognosing, staging, and monitoring MS in a sample are also provided, including methods for determining a subject as at risk for developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of a subject, and administering a pharmaceutically effective amount of a therapy (e.g., trebrutinib and potentially one or more additional therapies, e.g., an anti-CD20 therapy) to the subject.

This invention provides an anti-human CXCL13 rabbit monoclonal antibody, its preparation method, and its application, belonging to the field of immunoglobulin technology. This invention provides an anti-human CXCL13 rabbit monoclonal antibody that can specifically bind to the CXCL13 protein, significantly improving the specificity and sensitivity of immunoassay. It is suitable for preparing immunohistochemical detection kits and can accurately detect CXCL13 protein expression, providing a reliable tool for the diagnosis of diseases such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

Provided herein are methods and immune biomarkers for identifying progression and therapeutic selection of multiple sclerosis (MS). Also provided are materials and methods for prognosis, staging, and monitoring of MS in a sample, and including methods of determining that a subject is at risk of developing MS. The method comprises detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and / or CCL3, in the cerebrospinal fluid (CSF) of the subject; and administering to the subject a pharmaceutically effective amount of a treatment (e.g., tobutinib and potentially one or more additional therapies, such as an anti-CD20 therapy).

The invention relates to a CXCL13mRNA drug and an application of the CXCL13mRNA drug in tumor treatment. The present invention provides a lipid particle comprising an ionizable lipid, a phospholipid, a cholesterol, a PEG-lipid, and a CXCL13 mRNA encapsulated within the lipid particle. The invention also provides a pharmaceutical composition comprising the lipid particle and application thereof. The medicine containing CXCL13mRNA provided by the invention is particularly suitable for treating tumors including lung cancer, colorectal cancer, breast cancer, liver cancer, pancreatic cancer, head and neck cancer, brain glioma, melanoma and the like.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

This invention discloses a novel CD8 + T cells and CD4 + T cell subsets. The CD8... + T cell subsets include: subsets characteristically expressing GZMK and PDCD1; subsets characteristically expressing GZMK, GPR183, IL7R, and ZNF683; subsets characteristically expressing GZMK and CXCL13; subsets characteristically expressing GZMK and ZNF683; and subsets expressing at least one of the following KIR genes: KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL3. The CD4+... + T cell subsets include: subsets that characteristically express FOXP3, TNFRSF9, and CTLA4; and subsets that characteristically express FOXP3 and BACH1.